

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 1 (currently amended): A method of targeting a compound to a carcinoma or
2 fibrosarcoma cell over-expressing uPA and uPAR, the method comprising the steps of :

3 (i) administering to the carcinoma or fibrosarcoma cell a mutant protective
4 antigen protein comprising a uPA-recognized cleavage site in place of the native protective
5 antigen furin-recognized cleavage site, wherein the uPA-recognized cleavage site is PGSGRSA
6 (SEQ ID NO: 5), and wherein the mutant protective antigen is cleaved by uPA; and

7 (ii) administering to the carcinoma or fibrosarcoma cell a compound comprising a
8 lethal factor polypeptide comprising a protective antigen binding site; wherein the lethal factor
9 polypeptide binds to cleaved protective antigen and is translocated into the carcinoma or
10 fibrosarcoma cell, thereby delivering the compound to the carcinoma or fibrosarcoma cell.

2-8 (canceled)

1 9 (previously presented): The method of claim 1, wherein the carcinoma is lung.

10 (canceled)

1 11 (original): The method of claim 1, wherein the lethal factor polypeptide is
2 native lethal factor.

1 12 (original): The method of claim 1, wherein the compound is native lethal
2 factor.

1 13 (original): The method of claim 1, wherein the lethal factor polypeptide is
2 linked to a heterologous compound.

1 14 (original): The method of claim 13, wherein the compound is shiga toxin, A
2 chain of diphtheria toxin, or *Pseudomonas* exotoxin A.

15-17 (canceled)

1 18 (original): The method of claim 13, wherein the heterologous compound is
2 recombinantly linked to lethal factor.

1 19 (original): The method of claim 1, wherein the compound is a diagnostic or a
2 therapeutic agent.

1 20 (original): The method of claim 1, wherein the cell is a human cell.

1 21 (original): The method of claim 1, wherein the mutant protective antigen
2 protein is a fusion protein comprising a heterologous receptor binding domain.

1 22 (original): The method of claim 21, wherein the heterologous receptor
2 binding domain is selected from the group consisting of a single chain antibody and a growth
3 factor.

23-24 (canceled)

1 25 (previously presented): The method of claim 1, wherein the lethal factor
2 polypeptide comprises amino acids 1-254 of native lethal factor.

1 26 (previously presented): The method of claim 25, wherein the lethal factor
2 polypeptide is linked to a heterologous compound.

1 27 (previously presented): The method of claim 26, wherein the heterologous
2 compound is the ADP-ribosylation domain of *Pseudomonas* exotoxin A.

1 28 (previously presented): The method of claim 27, wherein the lethal factor
2 polypeptide is recombinantly linked to the ADP-ribosylation domain of *Pseudomonas*
3 exotoxin A.

1 29 (previously presented): The method of claim 27, wherein the lethal factor
2 polypeptide is covalently linked to the ADP-ribosylation domain of *Pseudomonas* exotoxin A by
3 a chemical bond.

1 30 (previously presented): The method of claim 13, wherein the compound is
2 covalently linked to lethal factor via a chemical bond.